BiotechTube
Home/Monopar Therapeutics/Andrew P. Mazar
AP

Andrew P. Mazar

Chief Scientific Officer

Monopar Therapeutics

Therapeutic Areas

OncologyRare Genetic Disorders

Monopar Therapeutics Pipeline

DrugIndicationPhase
ALXN1840Wilson DiseasePhase 3
MNPR-101-ZrAdvanced Solid Cancers (Imaging)Phase 1
MNPR-101-LuAdvanced Solid CancersPhase 1a
MNPR-101-AcAdvanced Solid CancersLate Preclinical

Leadership Team at Monopar Therapeutics

CR
Chandler Robinson
Chief Executive Officer
KR
Kim R. Tsuchimoto
Chief Financial Officer
CM
Christopher M. Starr
Chief Operating Officer
View full Monopar Therapeutics profile